تاريخ الإيرادات والأرباح والتدفقات النقدية من القوائم المالية الرسمية.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
الرسوم البيانية التفاعلية والقوائم الكاملة ← نموذج التقييم (DCF) ←
| قائمة الدخل | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 | 2015-03-31 | 2014-03-31 | 2013-03-31 | 2012-03-31 | 2011-03-31 | 2010-03-31 | 2009-03-31 | 2008-03-31 | 2007-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| إجمالي الإيرادات | ₹332.8B | ₹353.5B | ₹325.5B | ₹279.2B | ₹245.9B | ₹214.4B | ₹2.6B | ₹174.6B | ₹153.9B | ₹142.0B | ₹140.8B | ₹154.7B | ₹148.2B | ₹132.2B | ₹116.3B | ₹96.7B | ₹74.7B | ₹70.3B | ₹69.4B | ₹50.0B | ₹65.2B |
| إجمالي الربح | ₹166.9B | ₹186.5B | ₹190.4B | ₹163.6B | ₹139.3B | ₹113.8B | ₹1.3B | ₹94.0B | ₹83.4B | ₹76.3B | ₹78.4B | ₹92.3B | ₹85.4B | ₹75.8B | ₹60.6B | ₹53.3B | ₹40.3B | ₹36.3B | ₹36.5B | ₹25.4B | ₹30.9B |
| هامش الربح الإجمالي % | 50.1% | 52.8% | 58.5% | 58.6% | 56.7% | 53.1% | 50.8% | 53.8% | 54.2% | 53.7% | 55.6% | 59.7% | 57.6% | 57.4% | 52.1% | 55.1% | 53.9% | 51.7% | 52.6% | 50.8% | 47.4% |
| الدخل التشغيلي (EBIT) | ₹35.2B | ₹48.9B | ₹71.8B | ₹67.7B | ₹57.1B | ₹29.5B | ₹431M | ₹16.0B | ₹20.9B | ₹11.9B | ₹13.5B | ₹29.6B | ₹26.3B | ₹26.0B | ₹21.1B | ₹18.3B | ₹12.6B | ₹2.0B | (₹2.8B) | ₹3.4B | ₹11.3B |
| هامش التشغيل % | 10.6% | 13.8% | 22.1% | 24.3% | 23.2% | 13.8% | 16.9% | 9.2% | 13.6% | 8.4% | 9.6% | 19.1% | 17.7% | 19.7% | 18.2% | 18.9% | 16.9% | 2.9% | -4.1% | 6.7% | 17.2% |
| صافي الدخل | ₹33.2B | ₹45.1B | ₹56.5B | ₹55.7B | ₹45.1B | ₹23.6B | ₹232M | ₹19.5B | ₹18.8B | ₹9.8B | ₹12.0B | ₹20.0B | ₹22.2B | ₹21.5B | ₹16.8B | ₹14.3B | ₹11.0B | ₹1.1B | (₹5.2B) | ₹4.7B | ₹9.3B |
| هامش الربح الصافي % | 10.0% | 12.8% | 17.4% | 20.0% | 18.3% | 11.0% | 9.1% | 11.2% | 12.2% | 6.9% | 8.6% | 12.9% | 15.0% | 16.3% | 14.4% | 14.7% | 14.8% | 1.5% | -7.4% | 9.4% | 14.3% |
| EBITDA | ₹55.6B | ₹83.3B | ₹96.7B | ₹88.4B | ₹74.4B | ₹45.1B | ₹535M | ₹41.8B | ₹35.5B | ₹23.6B | ₹24.8B | ₹39.9B | ₹34.4B | ₹33.1B | ₹22.5B | ₹20.3B | ₹16.8B | ₹6.6B | ₹1.5B | ₹7.3B | ₹14.3B |
| ربحية السهم (EPS) | ₹39.81 | ₹54.11 | ₹67.77 | ₹66.80 | ₹54.17 | ₹28.34 | ₹0.28 | ₹23.48 | ₹22.62 | ₹11.80 | ₹14.42 | ₹23.40 | ₹25.95 | ₹25.21 | ₹19.69 | ₹16.76 | ₹12.99 | ₹1.26 | ₹-6.14 | ₹5.55 | ₹11.74 |
| الأسهم القائمة (م) | 833M | 833M | 834M | 834M | 832M | 832M | 832M | 830M | 831M | 831M | 835M | 855M | 855M | 853M | 852M | 851M | 850M | 848M | 842M | 843M | 796M |
المصدر: التقارير العامة للشركة (SEC). تحقق من SEC EDGAR قبل الاعتماد على أي رقم.
الميزانيات والتدفقات النقدية والبيانات الفصلية والنسب المالية الكاملة في العارض التفاعلي لـ RDY. /companies/us/RDY
المعلومات في هذا الموقع لأغراض تعليمية وإعلامية فقط ولا تشكل نصيحة استثمارية. لا تُنشر أسعار مستهدفة أو توصيات.
About TickerBase · Data methodology & sources · Privacy · Terms